cancers-logo

Journal Browser

Journal Browser

The Role of Ferroptosis in Cancer (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (30 April 2026) | Viewed by 981

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Pediatrics, Penn State College of Medicine, Hershey, PA, USA
2. Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, PA, USA
Interests: hippo pathway; brain tumor; tumor microenvironment; ferroptosis; regulated cell death
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the previous one, entitled "The Role of Ferroptosis in Cancer" (https://www.mdpi.com/journal/cancers/special_issues/WXRJVATTG0).

Ferroptosis is a type of regulated cell death (RCD) that depends on iron and is caused by a lethal accumulation of intracellular lipid peroxides. Since it was discovered more than a decade ago, studies have found that tumor cells, while able to resist other types of therapy-induced cell death, such as apoptosis, are sensitive to ferroptosis. These different responses have led to research exploring the therapeutic benefit of eliminating tumor cells through ferroptosis. Accumulating evidence has emerged to support this notion. On the other hand, ferroptotic cells, through releasing damage-associated molecular patterns (DAMPs) or other metabolites, can alter the tumor microenvironment, especially immune cells. This effect could be associated with enhanced immunogenicity; however, in certain situations, it may lead to sustained inflammation and have an immunosuppressive impact, thereby promoting tumor progression and therapeutic resistance. Methods to exploit ferroptosis to benefit cancer therapy while circumventing the potential tumor promotion effect are under intense study.

This Special Issue will highlight the latest advances in basic and translational research of ferroptosis in cancer, aiming to accelerate the speed in exploiting ferroptosis for cancer treatment.

Dr. Wei Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ferroptosis
  • cancer
  • reactive oxygen species
  • ROS
  • regulated cell death
  • RCD
  • immunogenic cell death
  • ICD
  • immunosuppression

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 3416 KB  
Article
Targeting Galectin-1 with Triptolide Induces Ferroptosis in Oral Squamous Cell Carcinoma
by Wei-Tso Chia, Cheng-Yu Yang, Wei-Chin Chang, Chang-Huei Tsao, Chih-Kung Lin, Sien-Lin Ho, Chin-Shan Kuo, Chi-Tsung Wu, Ching-Hsien Tsai, Yu-Hsuan Li, Kuei-Yuan Chen, Gu-Jiun Lin, Chun-Shu Lin, Cheng-Chih Hsieh and Yuan-Wu Chen
Cancers 2026, 18(5), 782; https://doi.org/10.3390/cancers18050782 - 28 Feb 2026
Viewed by 633
Abstract
Background: Oral squamous cell carcinoma (OSCC) remains clinically challenging, particularly in advanced disease, where treatment resistance limits therapeutic outcomes. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a potential anticancer vulnerability. Galectin-1 (Gal-1/LGALS1), a β-galactoside–binding [...] Read more.
Background: Oral squamous cell carcinoma (OSCC) remains clinically challenging, particularly in advanced disease, where treatment resistance limits therapeutic outcomes. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a potential anticancer vulnerability. Galectin-1 (Gal-1/LGALS1), a β-galactoside–binding lectin frequently overexpressed in OSCC, is associated with tumor progression and unfavorable prognosis; however, its involvement in ferroptosis regulation remains incompletely understood. Methods: To investigate whether Triptolide (TPL) influences ferroptosis-associated responses through Gal-1 modulation, OSCC cell lines (SAS and HSC-3) were treated with TPL and analyzed for cell viability, lipid reactive oxygen species (ROS) accumulation, and glutathione peroxidase 4 (GPX4) expression. Publicly available The Cancer Genome Atlas (TCGA) datasets were examined to evaluate Gal-1 expression patterns and survival associations. An OSCC xenograft mouse model was further used to assess the antitumor effects of TPL and changes in ferroptosis-related markers in vivo. Results: TPL treatment reduced cell viability and increased lipid ROS accumulation in OSCC cells, accompanied by downregulation of GPX4 expression. Gal-1 expression was also decreased following TPL exposure in vitro and in xenograft tumors. Analysis of TCGA data revealed that elevated Gal-1 expression was significantly associated with poorer overall survival in OSCC patients. Conclusions: These findings indicate that TPL induces ferroptosis-associated responses in OSCC and suggest that this effect is partly mediated through modulation of Gal-1 expression. Gal-1 may represent a clinically relevant factor influencing ferroptosis susceptibility, and targeting this pathway warrants further investigation as a potential therapeutic strategy for OSCC. Full article
(This article belongs to the Special Issue The Role of Ferroptosis in Cancer (2nd Edition))
Show Figures

Figure 1

Back to TopTop